Dermatomyositis Treatment Market Report 2026

The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to autoimmune disease recognition, corticosteroid availability, rheumatology clinic expansion, hospital-based immunotherapy, supportive care development.

The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to biologic pipeline expansion, precision immunology, early autoimmune screening, personalized treatment protocols, specialty clinic growth. Major trends in the forecast period include increased use of biologic therapies, growing reliance on immunosuppressive drugs, expansion of combination treatment approaches, rising adoption of long-term physical therapy, improved early diagnosis and disease monitoring.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the dermatomyositis treatment market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues. The rising prevalence of autoimmune conditions is attributed to improved diagnostic methods, greater awareness, and environmental factors, which collectively lead to higher detection rates and reported cases. Dermatomyositis treatments help address this trend by providing targeted therapies that reduce harmful immune activity and improve quality of life for affected patients. For instance, in February 2024, according to the Autoimmune Institute, a US-based nonprofit organization, autoimmune diseases collectively affect 5-10% of the population in industrialized countries. Therefore, the increasing prevalence of autoimmune diseases is boosting growth in the dermatomyositis treatment market.

Major companies in the dermatomyositis treatment market are focusing on developing innovative solutions, such as selective complement-pathway inhibitors, to meet the rising demand for safer, more targeted therapies that avoid the broad immunosuppression associated with traditional treatments. Selective complement-pathway inhibitors specifically block components of the complement cascade that drive inflammation in dermatomyositis, offering a more precise mechanism than conventional immunosuppressive agents. For example, in February 2025, NovelMed Therapeutics Inc., a US-based clinical-stage biotech company, received U.S. Food and Drug Administration (FDA) clearance to initiate a Phase II trial of Ruxoprubart (NM8074), a highly selective blocker of the alternative complement pathway targeting Factor Bb. Ruxoprubart modulates the immune response by reducing key inflammatory drivers while preserving essential immune functions, such as opsonization and bacterial clearance, potentially minimizing risks compared to broader complement blockers. The therapy is being evaluated for efficacy and safety in dermatomyositis patients.

In April 2025, Syneron Bio, a China-based biotechnology company, partnered with AstraZeneca to co-develop and commercialize innovative oral peptide therapies for chronic and autoimmune conditions. This collaboration combines Syneron Bio’s proprietary macrocyclic peptide technology with AstraZeneca’s global drug development expertise. AstraZeneca is a UK-based pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.

Major companies operating in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc.

North America was the largest region in the dermatomyositis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomyositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dermatomyositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the dermatomyositis treatment market by impacting imports of immunosuppressants, biologics, corticosteroids, and intravenous drug delivery materials. Biologic therapies and IVIG treatments are most affected, especially in North America and Europe where biologics are heavily imported. Hospital pharmacies face rising procurement expenses. On the positive side, tariffs are encouraging regional biologics manufacturing and pharmaceutical self-sufficiency.

The dermatomyositis treatment market research report is one of a series of new reports that provides dermatomyositis treatment market statistics, including dermatomyositis treatment industry global market size, regional shares, competitors with a dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatomycosis treatment involves the use of antifungal therapies to eliminate fungal infections of the skin. Mild to moderate infections are typically treated with topical antifungal creams or ointments such as clotrimazole, miconazole, or terbinafine. In more severe or resistant cases, oral antifungal medications like fluconazole or itraconazole may be prescribed.

The main treatment types for dermatomycosis include pharmacological treatments, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments use medications to manage symptoms and address the underlying cause of the disease. Routes of administration include oral, intravenous, and subcutaneous methods, with patient demographics categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals, home care providers, specialty clinics, and others.

The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.